Floating Zinc Gastric Delivery Compositions
A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.
1 . A composition comprising:
a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid, the dosage form having therein:
an active ingredient combination including an amino acid source and a zinc source;
an anionic polymer;
an effervescent agent; and
a pH buffer;
wherein the dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.
2 . The composition of claim 1 , wherein the zinc source is a water soluble zinc salt.
3 . The composition of claim 1 , wherein the anionic polymer has terminal carboxylate functional groups.
4 . The composition of claim 1 , wherein the pH buffer is in an amount capable of maintaining a substantially neutral pH within the dosage form while the dosage form is in contact with stomach acid.
5 . The composition of claim 1 , wherein the dosage form is therapeutically effective for treating a gastroesophageal condition.
6 . The composition of claim 1 , wherein the dosage form is a tablet.
7 . The composition of claim 1 , wherein the anionic polymer will swell upon contact with gastric fluid and a ratio of the anionic polymer to the zinc source is from 1:2 to 2:1.
8 . The composition of claim 1 , wherein the anionic polymer will swell upon contact with gastric fluid and the dosage form includes 100 to 500 mg zinc source and 100 to 500 mg of the anionic polymer.
9 . The composition of claim 1 , wherein the anionic polymer will swell upon contact with gastric fluid and the dosage form includes 200 to 300 mg zinc source and 200 to 300 mg of the anionic polymer.
10 . The composition of claim 1 , wherein the zinc source is 5% to 50% w/w of the dosage form.
11 . The composition of claim 1 , wherein the zinc source is 20% to 25% w/w of the dosage form.
12 . The composition of claim 1 , wherein the anionic polymer will swell upon contact with gastric fluid;
the anionic polymer is 20% to 25% w/w of the dosage form; and
the zinc source is 20% to 25% w/w of the dosage form.
13 . The composition of claim 1 , wherein the amino acid source is 2% to 10% w/w of the dosage form.
14 . A composition comprising:
a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid, the dosage form having therein:
2% w/w to 10% w/w of an amino acid source;
9% w/w to 45% w/w of a zinc source;
10% w/w to 55% w/w of an anionic polymer;
1% w/w to 15% w/w of a bicarbonate; and
wherein the dosage form is effective for releasing the amino acid source and zinc from the zinc source while buoyant on gastric fluid.
15 . The composition of claim 14 , wherein the zinc source is a water soluble zinc salt.
16 . The composition of claim 14 , wherein the anionic polymer has terminal carboxylate functional groups.
17 . The composition of claim 14 , wherein an amount of the bicarbonate is capable of maintaining a substantially neutral pH within the dosage form while the dosage form is in contact with stomach acid.
18 . The composition of claim 14 , wherein the dosage form is therapeutically effective for treating a gastroesophageal condition.
19 . The composition of claim 14 , wherein the dosage form is a tablet.
20 . The composition of claim 14 , wherein the anionic polymer will swell upon contact with gastric fluid and a ratio of the anionic polymer to the zinc source is from 1:2 to 2:1.
21 . The composition of claim 14 , wherein:
the anionic polymer will swell upon contact with gastric fluid;
the anionic polymer is 20% to 25% w/w of the dosage form; and
the zinc source is 20% to 25% w/w of the dosage form.
22 . The composition of claim 14 , wherein the anionic polymer will swell upon contact with gastric fluid and the dosage form includes 200 to 300 mg zinc source and 200 to 300 mg of the anionic polymer.
23 . The composition of claim 14 , wherein the amino acid source includes glutamine.
24 . A method of treating a gastroesophageal condition associated with stomach acid, the method comprising locally delivering zinc and an amino acid to a distal esophagus of a patient by administering to a patient in need thereof:
a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with the patient's gastric fluid, the dosage form having therein:
an active ingredient combination including an amino acid source and a zinc source;
an anionic polymer;
an effervescent agent; and
a pH buffer;
wherein the dosage form releases the active ingredient combination while buoyant on gastric fluid and neutralizes stomach acid while promoting healing of epithelial cells in the distal esophagus.
25 . The method of claim 24 , wherein the zinc source is a water soluble zinc salt.
26 . The method of claim 24 , wherein the anionic polymer has terminal carboxylate functional groups.
27 . The method of claim 24 , wherein the pH buffer is capable of maintaining a substantially neutral pH within the dosage form while the dosage form is in contact with stomach acid.
28 . The method of claim 24 , wherein the dosage form is therapeutically effective for treating a gastroesophageal condition.
29 . The method of claim 24 , wherein the dosage form is a tablet.
30 . The method of claim 24 , wherein the anionic polymer will swell upon contact with gastric fluid and a ratio of the anionic polymer to the zinc source is from 1:2 to 2:1.
31 . The method of claim 24 , wherein the anionic polymer will swell upon contact with gastric fluid and the dosage form includes 100 to 500 mg zinc source and 100 to 500 mg of the anionic polymer.
32 . The method of claim 24 , wherein the anionic polymer will swell upon contact with gastric fluid and the dosage form includes 200 to 300 mg zinc source and 200 to 300 mg of the anionic polymer.
33 . The method of claim 24 , wherein the zinc source is 5% to 50% w/w of the dosage form.
34 . The method of claim 24 , wherein the zinc source is 20% to 25% w/w of the dosage form.
35 . The method of claim 24 , wherein the anionic polymer will swell upon contact with gastric fluid;
the anionic polymer is 20% to 25% w/w of the dosage form; and
the zinc source is 20% to 25% w/w of the dosage form.
36 . The method of claim 24 , further comprising 2% to 10% w/w of an amino acid source.